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Abstract
Background: Sleep-disordered breathing (SDB) is highly prevalent in acute ischaemic stroke and is associated with
worse functional outcome and increased risk of recurrence. Recent meta-analyses suggest the possibility of
beneficial effects of nocturnal ventilatory treatments (continuous positive airway pressure (CPAP) or adaptive servo-
ventilation (ASV)) in stroke patients with SDB. The evidence for a favourable effect of early SDB treatment in acute
stroke patients remains, however, uncertain.
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Methods: eSATIS is an open-label, multicentre (6 centres in 4 countries), interventional, randomized controlled trial
in patients with acute ischaemic stroke and significant SDB. Primary outcome of the study is the impact of
immediate SDB treatment with non-invasive ASV on infarct progression measured with magnetic resonance
imaging in the first 3 months after stroke. Secondary outcomes are the effects of immediate SDB treatment vs non-
treatment on clinical outcome (independence in daily functioning, new cardio-/cerebrovascular events including
death, cognition) and physiological parameters (blood pressure, endothelial functioning/arterial stiffness). After
respiratory polygraphy in the first night after stroke, patients are classified as having significant SDB (apnoea-
hypopnoea index (AHI) > 20/h) or no SDB (AHI < 5/h). Patients with significant SDB are randomized to treatment
(ASV+ group) or no treatment (ASV− group) from the second night after stroke. In all patients, clinical, physiological
and magnetic resonance imaging studies are performed between day 1 (visit 1) and days 4–7 (visit 4) and repeated
at day 90 ± 7 (visit 6) after stroke.
Discussion: The trial will give information on the feasibility and efficacy of ASV treatment in patients with acute
stroke and SDB and allows assessing the impact of SDB on stroke outcome. Diagnosing and treating SDB during
the acute phase of stroke is not yet current medical practice. Evidence in favour of ASV treatment from a
randomized multicentre trial may lead to a change in stroke care and to improved outcomes.
Trial registration: ClinicalTrials.gov NCT02554487, retrospectively registered on 16 September 2015 (actual study
start date, 13 August 2015), and www.kofam.ch (SNCTP000001521).
Keywords: Sleep-disordered breathing, Stroke, MRI evolution, Treatment, Adaptive servo-ventilation, Randomized
controlled trial, Outcome
Background
Sleep-disordered breathing (SDB) is a highly prevalent
comorbidity in acute ischaemic stroke patients [1, 2].
About two-thirds of this patient group suffers from any
degree of SDB, up to 40% present an apnoea-hypopnea
index (AHI) above 20/h and one third even suffers from
a severe form with an AHI > 30/h [1–4].
A bidirectional relationship between SDB and stroke
can be assumed [5, 6]. SDB, especially the obstructive
subtype, is not only an independent risk factor for stroke
(e.g., [7]) but is also associated with a more rapid pro-
gression of stroke severity, with higher blood pressure
levels and longer hospitalization in the acute phase [8–
10]. Chronically, stroke patients with comorbid SDB ex-
hibit worse functional outcome and higher mortality [11,
12]. Several pathophysiological conditions associated
with SDB are believed to cause harmful effects [13].
These include intermittent hypoxemia, intrathoracic
pressure changes and sympathetic activation, which may
trigger cardiac arrhythmias or blood pressure swings [14,
15], potentially leading to harmful hypo- or hyper-
perfusion of acutely damaged brain tissue. The ischae-
mic penumbra may be amenable to reperfusion.
Consequently, any treatment stabilizing cerebral perfu-
sion and preserving constant brain tissue oxygenation
may be helpful [16].
Effective methods to normalize obstructive SDB are
available, including continuous positive airway pressure
(CPAP). However, central SDB is also often present in
acute stroke. Some studies even suggest that new-onset
SDB is often of central type [17, 18]. In particular,
central apnoeas and central periodic breathing were also
reported in patients with unilateral lesions of variable
topography without a disturbed level of consciousness or
overt heart failure, which potentially involve autonomic
or volitional brain areas participating in respiratory con-
trol [19]. Adaptive servo-ventilation (ASV) is considered
superior to CPAP in correcting both central and ob-
structive SDB [20]. Meta-analyses on the initiation of
SDB treatment in the very first days following stroke
postulate a positive association with neurofunctional
improvement with CPAP but with a considerable hetero-
geneity across the included trials [21]. Prior studies
reporting a positive impact of CPAP treatment after
acute stroke mainly included TIA patients, milder
strokes and younger patients. More recently, Bravata
and colleagues found better neurological functioning at
about 1 year post stroke, assessed with the modified
Rankin scale (mRS) and the National Institute of Health
Stroke Scale (NIHSS), in ischaemic stroke patients with
obstructive sleep apnoea (OSA) and compliant CPAP
use but not in the intention-to-treat analysis [22]. In this
study, CPAP was initiated with a median time delay of
about 2 months from onset of stroke symptoms. These
studies have not assessed the acute neuroradiological
evolution or change in network connectivity in the acute
stroke phase under ASV treatment versus no treatment.
Thus, eSATIS aims to investigate the effects of imme-
diate treatment of significant SDB (AHI > 20/h) with
non-invasive ASV started within 48 to 68 h after stroke
onset on the ischaemic lesion evolution assessed by
magnetic resonance imaging (MRI) 3 months after the
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event. The secondary trial objectives assess whether im-
mediate onset of ASV treatment in stroke patients with
SDB improves clinical stroke outcomes and physiological
parameters. The overall impact of significant SDB com-
pared to no SDB on theses outcomes is also assessed.
Methods
Study design and setting
The present study is a prospective, multicentre, random-
ized, open-label, rater-blinded clinical trial in ischaemic
stroke patients with SDB (AHI > 20/h, approximate re-
cruitment goal n = 134), including a control cohort of
stroke patients without SDB observed for the same
duration of time (no SDB; AHI < 5/h, approximate re-
cruitment goal n = 66). The study is conducted at 6
study sites in 4 countries: Bern University Hospital
(Switzerland), Cantonal Hospital St. Gallen
(Switzerland), Almazov National Medical Research
Centre St. Petersburg (Russia), Grenoble Alpes Univer-
sity Hospital (France), Medical Centre of the Johannes
Gutenberg University Mainz (Germany) and Charité -
Universitätsmedizin Berlin (Germany). It was designed
and initiated by an interdisciplinary research team of
neurologists, neuroradiologists and pulmonary physi-
cians at the Bern University Hospital and is coordinated
by this centre.
The trial was registered on ClinicalTrials.gov
(NCT02554487) on 16 September 2015 1 month after
recruitment of the first patient (first patient in 13 August
2015) as well as on www.kofam.ch (SNCTP000001521).
The initially monocentric trial became multicentre in
May 2017 as the second centre in Switzerland, St. Gal-
len, was initiated and was then successively extended to
Mainz, Berlin, St. Petersburg and Grenoble. Feasibility of
the trial at each centre was evaluated based on the num-
ber of admitted stroke patients to a centre, availability of
required infrastructure and qualified staff in the neces-
sary disciplines to conduct the trial: neurology, pulmon-
ary medicine and/or sleep medicine as well as
neuroradiology. Feasibility of diagnosing and treating
SDB in acute stroke patients was shown in former
clinical studies of the Bernese study team (SAS CARE 1
& 2, [23–25]).
Screening and recruitment procedures for the current
trial (described in the following paragraph) were estab-
lished and evaluated within clinical routine at the coord-
inating centre in Bern.
Screening and recruitment of participants
We recruit patients suffering from an ischaemic stroke
in the acute phase of stroke (hospitalization within 24 h
of symptom onset). Potential participants are identified
at admission to the emergency and stroke units of the 6
participating study sites following review of patients’
electronic medical records. Screening and recruitment
requires the presence of a study physician, the non-
invasive ventilation and MRI team and is usually
performed from Sunday night until Friday morning. In-
clusion and exclusion criteria are outlined in Table 1
and are checked according to a two-step screening algo-
rithm provided to all centres by the coordinating centre
of Bern.
First step
The study physician selects patients eligible for respira-
tory polygraphy depending on patients’ age (18–85
years), stroke location (supratentorial), stroke size on
diagnostic imaging and state of consciousness and re-
spiratory independence (no coma/intubation). After this
first screening step and depending on centres’ standard
operating procedures, a respiratory polygraphy is pre-
scribed within clinical routine or as part of the trial in
the first night after stroke. Accordingly, a study phys-
ician collects the patient’s or his/her next-of-kin’s/legal
representative’s informed consent before or after the re-
spiratory assessment.
Second step
Based on the result of the respiratory polygraphy, the
lesion diameter confirmed on the MRI at day 1, and
after the study physician has checked the remaining
exclusion criteria listed in Table 1, eligible patients
with significant SDB (AHI > 20/h) are randomized to
ASV treatment (SDB ASV+) versus no ventilation
treatment (SDB ASV−) applied between the 2nd and
89th night following stroke. Eligible patients with an
AHI < 5/h can be included into the control cohort
without SDB (noSDB group). Figure 1 gives an over-
view on the study design.
Every centre uses the same screening log. To identify
the main reasons why patients are not eligible and to
take action in case of potential screening and recruit-
ment difficulties, each centre sends its anonymized
screening log to the coordinating study team in Bern on
a regular basis. Based on the screening experience in
Bern before the trial became multicentre, eligibility cri-
teria were adapted to increase the number of potentially
eligible patients and generalizability of results. The main
adaptations included a reduction of inclusion AHI from
30/h to 20/h, extension of upper age limit from 80 to 85
and elimination of NIHSS > 4 as an inclusion criterion.
These modifications are trackable on clinicaltrials.gov.
Beside bi-annual investigator meetings, trial progres-
sion is also evaluated by the Swiss National Science
Foundation (SNSF), the main financial supporter of the
trial, based on bi-annual progress reports provided by
the coordination centre of Bern.
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To ensure retention and follow-up of each patient,
follow-up visits are planned together with the patients
and where possible combined with clinical routine visits.
A study nurse reminds patients of their onsite visit by a
phone call or letter and organizes the transport from
their home or rehabilitation unit to the hospital if neces-
sary. We also provide patients with our contact informa-
tion (e-mail, phone) and encourage them to call in case
of any also medical question.
Sleep assessment
Respiratory polygraphy is performed during the first
night following stroke onset using a Nox-T3 respiratory
polygraph (Nox Medical, Inc., Reykjavik, Iceland), ac-
cording to standard procedures provided by the manu-
facturer. This device allows the recording of nasal
pressure, snoring, rib cage and abdominal movement,
pulse oximetry, activity and body position.
Respiratory polygraphies are analysed by a certified
sleep physician immediately on the next day (visit 1,
study day 1) to allow inclusion of eligible participants
(Fig. 1). Respiratory polygraphies are repeated at visit 6
(day 90 ± 7) to examine the evolution of SDB following a
two-week washout period involving a temporary discon-
tinuation of ASV therapy.
Randomization
Random allocation of patients with significant SDB (n ~
134) (AHI > 20/h) in a 1:1 ratio to the two treatment
arms is performed using a list with permuted blocks and
stratified for the study centre and baseline AHI (AHI <
Table 1 Participant inclusion and exclusion criteria and criteria for randomization
Inclusion criteria Exclusion criteria
1. Informed consent as documented by signature
2. Admission to one of the participating centres
3. Age 18–85 years
4. Ischaemic stroke detectable by neuroimaging, affecting internal carotid
artery, anterior cerebral artery (ACA), middle cerebral artery (MCA),
posterior cerebral artery (PCA) and/or branches thereof
5. Symptom onset to admission < 24 h
6. AHI > 20/h or < 5/h
1. Primary haemorrhagic stroke or secondary parenchymal haemorrhage
(PH 1 and PH 2 according to ECASS)
2. Small strokes (diameter < 1.5 cm)
3. Coma/Stupor
4. Clinically unstable or life-threatening condition
5. Heart failure defined as congestive heart failure (CHF) functional class
NYHA III-IV OR CHF NYHA II and hospitalization caused by CHF in the
preceding 24months OR left ventricular ejection fraction ≤ 45%
6. Intubation or oxygen supply > 2 L/min.
7. Known progressive neurological diseases
8. Drug or alcohol abuse
9. Inability to follow study procedure
10. Pregnancy
11. Any given contraindications to MRI or MRI-contrast agent
12. Any given contraindications to ASV treatment
13. Protocol addendum made on 28.05.2020: Exclusion of patient with
clinical symptoms of COVID-19 infection (fever, signs of acute respiratory
infection, loss of taste or smell) during hospitalization due to acute
stroke*
Randomization criteria
1. AHI > 20/h
AHI apnoea-hypopnoea index, ASV adaptive servo-ventilation, ECASS European Cooperative Acute Stroke Study, MRI magnetic resonance imaging, NYHA New York
Heart Association
*Notes: COVID-19 testing algorithms of each centre apply and each centre must adhere to their country’s official standards and government guidelines
Fig. 1 Study flow chart. Ischaemic stroke patients admitted within
24 h of symptom onset undergo respiratory polygraphy on night 1.
Patients with AHI > 20/h are randomized to ASV versus no ASV
treatment. Patients with AHI < 5/h are followed in parallel. New
cerebro-cardiovascular events or death are assessed after 1 year by
telephone interview. Abbreviations: AHI, apnoea-hypopnoea index;
SDB, sleep-disordered breathing; ASV, adaptive servo-ventilation
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or ≥ 45/h assessed by respiratory polygraphy in the
screening night, visit 0). The trial statistician generated
the randomization list. Study physicians randomize pa-
tients using the electronic data capturing system after
obtaining the informed consent and evaluating all exclu-
sion and inclusion criteria. No study personnel, except
the trial statistician, has access to the randomization list
until completion of the trial.
Intervention: adaptive servo-ventilation
The investigational device for ASV in this trial is the
“AirCurve™10 CS PACEWAVE” device, (ResMed Ltd., 1
Elizabeth Macarthur Drive, Bella Vista NSW 2153,
Australia). It is indicated and approved for clinical use in
Switzerland, European Union, and other countries. For
this trial, the device is strictly applied in accordance to
its approved indications and the instruction manual.
Commercially available and approved full-face or nasal
masks are used as patient–ventilator–interface to
achieve optimal mask fit without relevant leakage. As in
clinical routine, all patients will undergo education and
training in the use of the device.
In case of an acute upper respiratory tract infection,
the intervention will be temporarily or constantly dis-
continued based on the study physicians and pulmonary
physicians’ decision. ASV treatment will be stopped if a
patient reports unusual chest pain, severe headache, in-
creased breathlessness or in case of new evidence for
congestive heart failure (as defined in the exclusion cri-
teria Table 1) and on patients’ request.
No comparator or sham treatment is administered. SDB
patients not randomized to ASV will be treated according
to best current medical practice. We decided against sham
ventilation due to the following reasons: (1) Sham ventila-
tion may cause even greater distress in patients than ef-
fective ventilation and patients will not perceive any
benefit in terms of an increase in sleep quality and an im-
provement in daytime sleepiness. This may lead to a
greater decrease in treatment compliance in sham versus
effectively treated patients. (2) As described by Tomfohr
and colleagues [26], stroke patients’ burden of a ventila-
tion intervention is already high and informing them that
they may be randomized to a placebo ventilation will fur-
ther decrease the number of given informed consents. (3)
The use of a subtherapeutic ventilation pressure may act
as a partial treatment of nightly occurring apnoeas and
hypopnoeas and thus decrease discriminatory power when
comparing the two randomized groups.
Assessment of outcomes
Primary outcome: final infarct change from visit 1 to visit 6
on magnetic resonance imaging (MRI)
The infarct volumes (measured in cm3) are assessed at
visit 1 and visit 6 (see Table 2 displaying which
assessments are performed at which visits, according to
[27]). We measure infarct volume on DWI (diffusion
weighted imaging) MRI scans at visit 1, i.e. after poten-
tial lysis therapy and before ASV-treatment, and on T2w
MRI scans at visit 6 (see Fig. 2 for illustration). Two in-
dependent raters blinded regarding patients’ treatment
allocation and presence of SDB assess the primary MRI
outcome supervised by two senior neuroradiologists.
Change of lesion volume from visit 1 to visit 6 is com-
pared between the treatment groups (SDB ASV+ and
SDB ASV−). Change of lesion volume from visit 1 to
visit 6 will also be compared between the patient groups
with sleep-disordered breathing (SDB ASV+ and ASV−
together) and without sleep-disordered breathing
(noSDB).
Secondary outcome measurements
Demographics Study physicians and stroke neurologists
collect patients’ demographical data during the first 1–2
days following stroke.
Stroke data/localization/treatment At visit 1, study
physicians record stroke-specific data such as time of
stroke and stroke localization. Antithrombotic treatment
before admission (anticoagulation, antiplatelet agents,
antihypertensive drugs, cardiac drugs) and thrombolysis
at admission is noted. Additional assessments of pre-
stroke cardiovascular risk factors are performed: family
history, arterial hypertension (BP ≥ 140/90 mmHg mea-
sured ≥ 3 times before stroke or patients under treat-
ment for hypertension), diabetes (fasting glucose level ≥
140 mg/dL or patients treated for diabetes), smoking sta-
tus, alcohol intake, hypercholesterolemia (cholesterol
level ≥ 250 mg/dL or previously under statins) and previ-
ous history of coronary heart disease or heart failure,
and a validated cerebrovascular risk score (“the Essen
Stroke Risk Score, ESRS”) will be determined [28].
Medical history including medication Study physi-
cians record the pre-stroke medical history including
medication and treatments at discharge. Assessment of
post-stroke medical history including medication is re-
peated during visit 6 and visit 7 and includes all relevant
diseases that (i) have been diagnosed by a physician and/
or that (ii) have been treated (pharmacologically or non-
pharmacologically).
Assessment of stroke severity and clinical outcome
 Stroke severity is assessed by means of the NIHSS at
admission (visit 0), after 24 h (visit 1), at patient’s
hospital dismissal (visit 4) and at the 90 ± 7 days’
follow-up during visit 6.
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Table 2 Summary of assessment at each time point according to SPIRIT guidelines
*The following assessments will be collected as long as they are performed within the clinical routine. **Routine analyses: total cholesterol, LDL, HDL, triglycerides,
glycated haemoglobin (HbA1c), glucose, C-reactive protein (CRP), thrombocytes, INR, PTT and fibrinogen. Inflammatory markers (optional, depending on funding):
MMP-9, TIMP-1, TIMP-4 and sVCAM-1. ***Clinical baseline. Black bars indicate that an assessment can be performed within the indicated timeframe
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 Modified Rankin Scale (mRS) [29] is used to
characterize patient’s (in)dependence in daily
functioning and in performance of daily activities
before the stroke and will be assessed before hospital
discharge (between visits 1 and 4).
 Clinical stroke outcomes are assessed at visit 6 and
visit 7 using the Barthel Index (BI) [30] and the mRS
[29] as well as patient’s subjective rating about
quality of life (EQ-5D-3L) [31].
 Sensorimotor upper extremity functions are assessed
by the Fugl-Meyer Assessment of upper extremities,
which has provided to be reliable and sensitive to as-
sess upper-extremity recovery following stroke at 4
to 7 days after stroke and at 3-month follow-up (visit
4 and 6) [32, 33].
 Death and new cardio-/cerebrovascular events: a
composite endpoint of death from any cause, stroke,
transient ischaemic attack (TIA), nonfatal
myocardial infarction, unplanned hospitalization (or
unplanned prolongation of a planned
hospitalization) for heart failure or unplanned
hospitalization (or unplanned prolongation of a
planned hospitalization) leading to urgent
revascularization is assessed at visit 4, visit 6, and
visit 7 (see Additional file, table 1 for a definition of
the events)
 Cognitive outcomes: Cognitive performance
measures, assessed by neuropsychological tests (see
Additional file, table 2 for details) of language,
neglect, attention, executive functions and verbal
and visual short-and long-term memory, are ob-
tained at visit 4 and visit 6.
Physiological assessments
 Body measurements: Body weight-related measures
are assessed at visit 1 and visit 6. Measures include:
height in metre and body weight in kg in order to
calculate BMI (kg/m2), neck circumference, waist
(taken at the narrowest waist level) and hip (taken at
the level of hip bones) circumference to calculate
the Waist/Hip-Ratio (WHR), abdominal circumfer-
ence (taken at the level of the umbilicus).
 Blood pressure (BP): (1) acute phase: supine BP is
measured at the non-paralyzed arm using a non-
invasive BP monitoring device at each site’s stroke
unit. Mean systolic and diastolic BP values and min-
imal and maximum values are calculated for the in-
dividual patients. BP variability is calculated by
standard deviation, coefficient of variation and max-
imum minus minimum of both diastolic and systolic
values. Night and day parameters can be analysed
separately. (2) At hospital dismissal (after visit 4)
and at 3 months following stroke (before visit 6): a
3-week BP-monitoring is performed with an ambula-
tory device (Boso Medicus PC 2, Bosch & Sohn,
Germany). Measurements are performed up to 3
times successively, 3 times a day (morning, noon,
evening) in a sitting position by the patients them-
selves or the caregivers. The devices themselves
store the measurements automatically. At the same
time patients are filling in a diary. Mean systolic and
diastolic BP values and minimal and maximum
values are calculated for the individual patients over
the whole period. BP variability is calculated as men-
tioned above.
 Endothelial functioning and arterial stiffness:
endothelial function and arterial stiffness is assessed
with peripheral arterial tonometry (PAT) (EndoPAT
2000, ItamarMedical Ltd., Caesarea, Israel) in the
acute phase at visit 3 and the chronic phase at visit
6 as described in Patvardhan and colleagues [34]. All
calculated parameters are summarized in the
Additional file, table 3.
 Blood coagulation parameters and inflammatory
blood markers: blood is sampled from a
venepuncture for routine and complementary blood
tests at visit 2 and 6. Blood sampling for routine
analysis of total cholesterol, low- and high-density
lipoprotein (LDL and HDL) triglycerides, glycated
haemoglobin (HbA1c), glucose, C-reactive protein
Fig. 2 Assessment of primary endpoint. Infarct volume is manually segmented on DWI (diffusion weighted imaging) MRI scans at visit 1, i.e. after
potential lysis therapy and before ASV-treatment, and on T2w MRI scans at visit 6. The lesion mask (volume of interest, VOI) is used to preselect
the lesion on the T2w images and manual correction is then applied
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(CRP), thrombocytes, international normalized ratio
(INR), partial thromboplastin time (PTT) and fi-
brinogen is done according to the hospital protocol
and analysed locally. Blood samples of approximately
50 mL are obtained from each patient. Optionally
(depending on funding), remaining blood samples
will be stored at each site for up to 15 years to be
reanalysed for inflammatory markers: MMP-9,
TIMP-1, TIMP-4 and sVCAM-1. In the informed
consent form, patients are informed and agree with
the storage of biological specimens, if applicable.
Assessment of ASV treatment compliance Compliance
to ASV treatment is checked daily during the initiation of
ASV treatment using the devices internal recordings.
Thereafter, verification of compliance takes place at clin-
ical controls at visits 2, 4, 5 and 6. Sufficient compliance is
defined as a cumulative ASV use in ≥ 70% of all nights
and ≥ 4 h per night in the first 3 months after stroke. All
patients who started ASV treatment/training will be ana-
lysed as ASV patients (intention to treat; ITT). For sec-
ondary analyses, patients with SDB are stratified according
to their compliance: compliant patients (per protocol, PP)
will be compared to non-compliant participants and to
participants who did not receive ASV-treatment.
Pre- and post-stroke sleep history and sleep
questionnaires
 Pre-stroke sleep history: at days 1 to 4 following
stroke, patients are shortly interviewed about pre-
stroke sleep problems. Interview questions include
(1) questions about usual bedtime, sleep latency, rise
time and sleep duration during the week and on the
weekends within the last month before stroke, (2)
bed- and rise time and sleep duration during the
two nights before stroke, (3) daytime naps the 2 days
before stroke and (4) any previous significant sleep
disturbances within the last month before stroke
and intake of medication.
 Post-stroke sleep history is assessed at visit 6 and 7
and include (1) questions about usual bedtime, sleep
latency, rise time and sleep duration during the
week and at the weekends within the last month
from now and (2) occurrence of any significant sleep
disturbances within the last month and intake of
medication.
 Sleep and depression questionnaires: all stroke
patients fill in the following questionnaires to
measure sleepiness/fatigue, likelihood for sleep
apnoea and symptoms of depression at visits 1, 6
and 7:
1) Epworth Sleepiness Scale (ESS) [35].
2) Fatigue Severity Scale (FSS) [36]
3) Berlin Questionnaire for Sleep Apnoea (BQSA)
[37]
4) Beck Depression Inventory (BDI-II) (validated
German translation of [38])
Data collection of primary and secondary outcome
measurements continues even if a patient of the ASV+
group discontinues ASV treatment. The only condition
when data collection stops is if patients withdraw their
informed consent. Data collected until this point in time
will be kept and analysed as agreed by patients signing
the informed consent forms.
Data management and study monitoring
The case report forms (CRFs) in this trial are imple-
mented electronically using a dedicated electronic data
capturing (EDC) system (REDCap). The EDC system
was activated for the trial only after successfully passing
a formal test procedure. All data entered in the elec-
tronic CRFs are stored on a Linux server in a dedicated
mySQL database.
Study monitoring including source data verification of
a selected subject at each centre is performed by the
Clinical Trial Unit (CTU) of the University of Bern,
Switzerland. With the informed consent, patients agree
that relevant data can be viewed and shared with the re-
search team that initiated the study (coordinating re-
search team in Bern), with the ethical and regulatory
authorities (including the representative of the trial’s in-
surance in case of a potential study-related damage) and
the trial’s monitors.
Statistical analysis
Descriptive summary statistics for efficacy and safety
variables will be presented for the entire population and
by study arm (no SDB patients, and SDB patients ran-
domized to the ASV+ and ASV- arms). Inferential statis-
tical methods will be used to highlight interesting
aspects of the data and primarily for the comparison of
outcome variables in the two randomized arms. In
addition, comparisons of selected outcomes will be car-
ried out between the two cohorts. The significance level
of all statistical tests will be 5% and no control for multi-
plicity will be applied. Corresponding 95% confidence in-
tervals will be presented as appropriate.
Two main analysis populations will be used:
 Full Analysis Set (FAS): this population will include
all enrolled patients. In line with the intent-to-treat
principle, randomized patients will be analysed ac-
cording to the treatment group assigned at
randomization. The FAS will be the main analysis
population for efficacy and safety variables. In par-
ticular, it will be the primary population for the
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comparative analysis of the two randomized treat-
ment groups.
 Per-protocol (PP) population: it will include
randomized patients fulfilling all selection criteria
and sufficiently compliant with the protocol. The list
of criteria, leading to exclusion from the PP analysis,
which, among other criteria, will consider the
compliance with ASV procedures, will be finalized
before database closure for the primary analysis.
The comparative analysis of infarct volume data will
be performed using an analysis of covariance model with
adjustments at least for the stratification variables used
at randomization. In case of violation of the statistical
validity conditions for the model, a suitable non-
parametric alternative model will be employed, such as
the Van Elteren test.
Between-arm comparisons of continuous variables will
be performed using the same methodology as for the
primary variable, whereas models may include additional
explanatory variables, such as the baseline value of spe-
cific outcome variables assessed at study end. Logistic
regression will be used for comparisons based on binary
variables.
Furthermore, similar models will be used to compare
outcome variables between patients from the two co-
horts of randomized patients and no SDB patients. Due
to the non-randomized design and the definition of the
cohorts, the set of explanatory variables included in
these models will be different: AHI will not be included,
but other potential confounders, such as age and gender
may be. No interim analysis of efficacy endpoints is
planned. Primary and secondary efficacy outcomes will
be analysed after all randomized patients have completed
the study or have left it prematurely. Interim analyses of
safety may be performed. The analysis of safety data will
use descriptive statistical methods. Deviations from the
analyses outlined in this section and in the statistical
analysis plan will be listed and justified in the Clinical
Study Report. No imputation of missing variables will be
employed in the primary comparative analysis of efficacy
parameters in the two randomization groups. For sup-
portive analyses, imputation strategies considered con-
servative may be used.
Power calculation and sample size
Based on feasibility considerations, approximately 134
patients are expected to be randomized in a 1:1 propor-
tion into the group with ASV treatment and without
ASV treatment (SDB ASV+ and SDB ASV-). Based on a
two-sided t test at the 5% significance level, this sample
size will provide at least 80% power to detect an effect
size (Cohen’s d) of 0.49 for the between-group difference
in primary outcome (difference in infarct size from visit
1 (day 1) to visit 6 (day 90)). Based on preliminary inves-
tigations in a similar patient pool, the standard deviation
is assumed to be 20 cm3 (unpublished data), so that the
detectable effect size corresponds to a between-arm dif-
ference of approximately 10 cm3. In secondary analyses,
the outcomes will be compared in patients with and
without SDB: the detectable difference is expected to be
approximately 10 cm3 also for this analysis. Calculations
were performed using the statistical software package R
(https://www.r-project.org/) [39]. These differences are
considered meaningful from a clinical point of view.
Based on these considerations, the planned sample size is
considered adequate to address the main study objective.
Safety
Serious adverse events (SAE), serious adverse device effects
(SADE) and serious adverse incidents (SAI) are assessed at
each centre and reported to the centres’ local ethical com-
mittees according to their requirements and within 24 h of
awareness to the coordinating centre in Bern.
The coordinating centre in Bern also submits an an-
nual safety report to their ethical committees and to
centres’ principal investigators (PI). All PIs are respon-
sible to continuously evaluate the risk-benefit profile of
the intervention for each examined patient. Findings or
available data indicating an imbalanced risk-benefit pro-
file must be reported to the ethical authorities and the
PIs must take the necessary steps.
In case of a SAI, each centre will contact the respon-
sible person for medical device vigilance in order to de-
cide whether reporting to the national health
surveillance authorities according to the legal require-
ments at each centre is indicated.
Discussion
eSATIS trial is the first trial to assess the impact of
immediate treatment of significant SDB (AHI > 20/h)
in acute ischaemic stroke patients with non-invasive
ASV on infarct progression in a prospective interven-
tional randomized controlled design. The trial will
give information on the feasibility and efficacy of
ASV treatment in patients with stroke and SDB and
allow assessing the impact of SDB on stroke outcome.
Diagnosing and treating SDB during the acute phase
of stroke is not yet current medical practice. Evidence
in favour of ASV treatment from a randomized multi-
centre trial may lead to a change in stroke care and
to improved outcomes.
Limitations of this trial include the following: (1)
The compliance to ASV is expected to be around
50%. This will have an impact on the interpretation
of results. (2) The treatment is open label, which may
result in a bias affecting the assessment of secondary
clinical outcomes. However, sham ventilation may
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cause even greater distress in patients than effective
ASV treatment without beneficial effects on sleep
quality and improvement of daytime sleepiness and is
ethically questionable. (3) It is unknown whether the
sample size of 134 randomized patients will be suffi-
cient to detect the real treatment effect, since no data
on the impact of ASV treatment on the evolution of
the lesion volume are available so far.
Trial status
Recruitment started in August 2015 at the coordinating
centre of the Bern University Hospital and was successively
expanded to the other centres: Cantonal Hospital St. Gallen
(Switzerland), Almazov National Medical Research Centre
St. Petersburg (Russia), Grenoble Alpes University Hospital
(France), Medical Centre of the Johannes Gutenberg Uni-
versity, Mainz (Germany) and Charité - Universitätsmedi-
zin Berlin (Germany). Recruitment is expected to be
completed in July 2021. The current version of the protocol
is version 4.1 dated 07.02.2017.
Supplementary Information




AHI: Apnoea-hypopnoea index; ASV: Adaptive servo-ventilation; BDI-II: Beck
Depression Inventory II; BI: Barthel Index; BP: Blood Pressure; BQSA: Berlin
Questionnaire for Sleep Apnoea; CHF: Congestive Heart Failure;
CPAP: Continuous positive airway pressure; CRFs: Case report forms;
CSA: Central sleep apnoea; CTU: Clinical Trial Unit; DWI: Diffusion weighted
imaging; ECASS: European Cooperative Acute Stroke Study; EDC: Electronic data
capturing; ESS: Epworth Sleepiness Scale; FAS: Full analysis set; FSS: Fatigue
Severity Scale; ITT: Intention to treat; MRI: Magnetic resonance imaging;
mRS: modified Rankin Scale; NIHSS: National Institute of Health Stroke Scale;
NYHA: New York Heart Association; OSA: Obstructive sleep apnoea; PI: Principal
investigator; PP: Per protocol; SADE: Serious adverse device effects; SAE: Serious
adverse events; SAI: Serious adverse incidents; SDB: Sleep-disordered breathing;
TIA: Transient ischaemic attack; VOI: Volume of interest
Acknowledgements
We gratefully acknowledge the administrative and logistical assistance of our
study physicians, study nurses and study coordinators during study
preparation and conduct: Andrea Seiler, Michael Oberholzer, Corina Gorban-
Peric, Doris Kuen, Julian Lippert, Filip Alexiev, Martijn Dekkers, Christian Hor-
vath, Nadja Steiner, Nicole Duttweiler and Tanja Gerber (Bern, Switzerland),
Fabienne Grünenfelder, Anna Müller (St. Gallen, Switzerland), Sandra Paryjas
(Mainz), Kirstin Brade (Berlin, Germany), Maria Golovkova, Valeria Kemstach,
Anton Ryzhkov, Mikhail Bochkarev, Elena Medvedeva, Denis Obukhov, Vlad-
imir Fokin, Aluzmin, Kayum Simakov, Aleksandra Konradi (St. Petersburg,
Russia), and Olivier Detante, Alexandre Krainik, Marjorie Dole, Sylvie Grand,
Johan Pietras and Sarah Alexandre (Grenoble, France).
We thank our advisory board—Hans Christoph Diener (University Hospital
Essen, Germany), Patrick Levy (Grenoble Alpes University, Grenoble, France),
Walter McNicholas (University College Dublin, Ireland), Winfried Randerath
(University Solingen, Germany), Max Wintermark (Stanford University Medical
Center, USA), and Greg Zaharchuk (Stanford University Medical Center,
USA)—for their advice during protocol development and for reviewing the
protocol.
The authors would also like to acknowledge individuals with stroke for their
participation in this research study and the assistance of the clinical teams
on the stroke units and during adaptive servo-ventilation application.
Authors’ contributions
CLAB conceived the study, received the funding and is the most responsible
investigator who will together with the main study coordinator SBD and
MHS oversee data collection at all sites. DF, YW/HG, ME/FS, LK/YS and JLP
are co-principal investigators responsible for study conduct and data collec-
tion at the study sites St. Gallen, Mainz, Berlin, St. Petersburg and Grenoble,
respectively. SRO and RW are the main co-investigators in Bern. RW and ND
are responsible for MRI acquisition and analysis. CB is the trial statistician re-
sponsible for statistical analysis plan and data analysis. The study was con-
ceived and is conducted with input from SBD, AKB, SB, FS, CB, LK, YS, MHS,
TH, FZ and MA. Authors and acknowledged co-workers will be involved in
the data analysis and preparation of various outcome measures. SBD, AKB
and SB wrote this protocol manuscript, the final version of which all authors
have reviewed and approved.
Funding
This work is supported by the Swiss National Science Foundation (grant nr.
320030_149752 and grant nr. 33IC30_166827) and the TROPOS Foundation
Switzerland (Stiftung für Humane Verhaltensforschung). The company
ResMed supports the trial with the interventional study devices (adaptive
servo-ventilation (ASV) devices), respiratory polygraphy devices to assess
sleep-disordered breathing during the acute and chronic phase of stroke, dis-
pensable material and financially by supporting the conduct of the bi-annual
study meetings. All funders have no role in the study design, recruitment,
data collection and/or analyses, preparation and review/approval of all publi-
cations resulting from the current trial.
Availability of data and materials
Not applicable as the study is ongoing. After study completion and
publication of the results, the datasets generated and/or analysed during the
current study will be available from the corresponding author on reasonable
request.
Ethics approval and consent to participate
This trial is conducted in full compliance with Good Clinical Practice and
according to the local law and regulatory requirements at each participating
centre.
Switzerland: Ethical Committee Bern, Murtenstrasse 31, 3010 Bern, Switzerland
(lead ethical committee in Switzerland) and Ethical Committee EKOS (local
ethical committee in Switzerland), Oberer Graben 32, 9001 St. Gallen,
Switzerland (ethical number: PB_2016-01494, date of approval: 25.03.2015/,
date of approval of last amended protocol version 4.1 dated 07.02.2017:
23.02.2017).
Germany: Ethik-Kommission, Landesärztekammer Rheinland-Pfalz, Postfach 29
26, 55019 Mainz (ethical number: 837.250.17 (11084), date of approval
30.01.2018).
France, Grenoble: CPP Sud-Est VI – CHU – Administration Centrale – 58 rue
Montalembert – BP.69 – 63003 Clermont Ferrand Cedex 1 (Ref. CPP: AU1392;
Ref. ID-RCB 2017-A02877-46, date of approval 03.04.2018).
Russia: Ethical Committee of the Almazov National Medical Research Centre,
2 Akkuratov str., St. Petersburg, 197341 Russia (Ethical approval number 7
dated 15.01.2018 and number 88-A dated 14.05.2018).
Any protocol modifications will be communicated to the responsible ethical
committees. Written, informed consent to participate is obtained from all
participants prior to their inclusion in the study.
Consent for publication
Consent for publication is obtained for every participant included in the
study. The results of the eSATIS trial will be presented at national and
international conferences and will be published in peer-reviewed journals.
Additionally, a summary of the study’s findings will be posted on the eSATIS
website (www.esatis.ch). Patients’ confidentiality will be strictly guaranteed.
Only the sites’ study teams know patients’ identity.
Competing interests
The authors declare that they have no competing interests.
Duss et al. Trials           (2021) 22:83 Page 10 of 11
Author details
1Department of Neurology, Bern University Hospital (Inselspital) and
University of Bern, Bern, Switzerland. 2Interdisciplinary
Sleep-Wake-Epilepsy-Center, Bern University Hospital (Inselspital) and
University of Bern, Bern, Switzerland. 3Department of Pulmonary Medicine,
Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland.
4Grenoble Alpes University, HP2 Laboratory, INSERM U1042, Grenoble, France.
5Pôle Thorax et Vaisseaux, Grenoble Alpes University Hospital, Grenoble,
France. 6Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen,
Switzerland. 7Department of Pneumology, Cantonal Hospital St Gallen, St.
Gallen, Switzerland. 8Hypertension Department, Somnology Group, Almazov
National Medical Research Centre, St. Petersburg, Russia. 9Department of
Neurology, Center for Stroke Research Berlin (CSB), Charité – University
Medicine Berlin, Berlin, Germany. 10Department of Otorhinolaryngology,
Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
11Department of Neurology, Medical Centre of the Johannes Gutenberg
University, Mainz, Germany. 12University Institute of Diagnostic and
Interventional Neuroradiology, Bern University Hospital (Inselspital) and
University of Bern, Bern, Switzerland. 13Department of Neurology, Sechenov
University, Moscow, Russia.
Received: 17 September 2020 Accepted: 15 December 2020
References
1. Seiler A, Camilo M, Korostovtseva L, Haynes AG, Brill AK, Horvath T, et al.
Prevalence of sleep-disordered breathing after stroke and TIA: a meta-
analysis. Neurology. 2019;92(7):e648–e54.
2. Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA
patients: a meta-analysis. J Clin Sleep Med. 2010;6(2):131–7.
3. Hermann DM, Bassetti CL. Sleep-related breathing and sleep-wake
disturbances in ischemic stroke. Neurology. 2009;73(16):1313–22.
4. Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing and acute
ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term
clinical outcome. Stroke. 2006;37(4):967–72.
5. Bassetti CLA. Sleep and stroke: a bidirectional relationship with clinical
implications. Sleep Med Rev. 2019;45:127–8.
6. Duss SB, Brill AK, Bargiotas P, Facchin L, Alexiev F, Manconi M, et al. Sleep-
wake disorders in stroke-increased stroke risk and deteriorated recovery? An
evaluation on the necessity for prevention and treatment. Curr Neurol
Neurosci Rep. 2018;18(10):72.
7. Kendzerska T, Mollayeva T, Gershon AS, Leung RS, Hawker G, Tomlinson G.
Untreated obstructive sleep apnea and the risk for serious long-term
adverse outcomes: a systematic review. Sleep Med Rev. 2014;18(1):49–59.
8. Iranzo A, Santamaria J, Berenguer J, Sanchez M, Chamorro A. Prevalence
and clinical importance of sleep apnea in the first night after cerebral
infarction. Neurology. 2002;58(6):911–6.
9. Kaneko Y, Hajek VE, Zivanovic V, Raboud J, Bradley TD. Relationship of sleep
apnea to functional capacity and length of hospitalization following stroke.
Sleep. 2003;26(3):293–7.
10. Selic C, Siccoli MM, Hermann DM, Bassetti CL. Blood pressure evolution after
acute ischemic stroke in patients with and without sleep apnea. Stroke.
2005;36(12):2614–8.
11. Bassetti C, Milanova M, Gugger M. Sleep disordered breathing and acute
stroke: diagnosis, risk factors, treatment, and longterm outcome. Stroke.
2006;37:967–72.
12. Parra O, Arboix A, Montserrat JM, Quinto L, Bechich S, Garcia-Eroles L. Sleep-
related breathing disorders: impact on mortality of cerebrovascular disease.
Eur Respir J. 2004;24(2):267–72.
13. Barlinn K, Alexandrov AV. Sleep-disordered breathing and arterial blood flow
steal represent linked therapeutic targets in cerebral ischaemia. Int J Stroke.
2011;6(1):40–1.
14. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea:
implications for cardiac and vascular disease. JAMA. 2003;290(14):1906–14.
15. Wolk R, Kara T, Somers VK. Sleep-disordered breathing and cardiovascular
disease. Circulation. 2003;108(1):9–12.
16. Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology.
1996;47(4):884–8.
17. Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: final
report on 128 patients. Sleep. 1999;22(2):217–23.
18. Parra O, Arboix A, Bechich S, Garcia-Eroles L, Montserrat JM, Lopez JA, et al.
Time course of sleep-related breathing disorders in first-ever stroke or transient
ischemic attack. Am J Respir Crit Care Med. 2000;161(2 Pt 1):375–80.
19. Siccoli MM, Valko PO, Hermann DM, Bassetti CL. Central periodic breathing
during sleep in 74 patients with acute ischemic stroke - neurogenic and
cardiogenic factors. J Neurol. 2008;255(11):1687–92.
20. Baillieul S, Revol B, Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Pepin JL.
Diagnosis and management of central sleep apnea syndrome. Expert Rev
Respir Med. 2019;13(6):545–57.
21. Brill AK, Horvath T, Seiler A, Camilo M, Haynes AG, Ott SR, Egger M, Bassetti
CL. CPAP as treatment of sleep apnea after stroke: A meta-analysis of
randomized trials. Neurology. 2018;90(14):e1222–30.
22. Bravata DM, Sico J, Vaz Fragoso CA, Miech EJ, Matthias MS, Lampert R, et al.
Diagnosing and treating sleep apnea in patients with acute cerebrovascular
disease. J Am Heart Assoc. 2018;7(16):e008841.
23. Bernasconi C, Ott SR, Fanfulla F, Miano S, Horvath T, Seiler A, et al. SAS CARE
2 – a randomized study of CPAP in patients with obstructive sleep
disordered breathing following ischemic stroke or transient ischemic attack.
Sleep Med X. 2020;2:100027.
24. Cereda CW, Petrini L, Azzola A, Ciccone A, Fischer U, Gallino A, et al. Sleep-
disordered breathing in acute ischemic stroke and transient ischemic attack:
effects on short- and long-term outcome and efficacy of treatment with
continuous positive airways pressure--rationale and design of the SAS CARE
study. Int J Stroke. 2012;7(7):597–603.
25. Ott SR, Fanfulla F, Miano S, Horvath T, Seiler A, Bernasconi C, et al. SAS Care
1: sleep-disordered breathing in acute stroke an transient ischaemic attack -
prevalence, evolution and association with functional outcome at 3 months,
a prospective observational polysomnography study. ERJ Open Res. 2020;
6(2):00334–2019.
26. Tomfohr LM, Hemmen T, Natarajan L, Ancoli-Israel S, Loredo JS, Heaton RK,
Bardwell W, Mills PJ, Lee RR, Dimsdale JE. Continuous positive airway
pressure for treatment of obstructive sleep apnea in stroke survivors: what
do we really know? Stroke. 2012;43(11):3118–23.
27. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K,
et al. SPIRIT 2013 statement: defining standard protocol items for clinical
trials. Ann Intern Med. 2013;158(3):200–7.
28. Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, et al. The
Essen stroke risk score predicts recurrent cardiovascular events: a validation
within the REduction of Atherothrombosis for Continued Health (REACH)
registry. Stroke. 2009;40(2):350–4.
29. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J.
Interobserver agreement for the assessment of handicap in stroke patients.
Stroke. 1988;19(5):604–7.
30. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State
Med J. 1965;14:61–5 PMID: 14258950.
31. EuroQol Group. EuroQol-a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16:199–208.
32. Rabadi MH, Rabadi FM. Comparison of the action research arm test and the
Fugl-Meyer assessment as measures of upper-extremity motor weakness
after stroke. Arch Phys Med Rehabil. 2006;87(7):962–6.
33. Sullivan KJ, Tilson JK, Cen SY, Rose DK, Hershberg J, Correa A, et al. Fugl-Meyer
assessment of sensorimotor function after stroke: standardized training
procedure for clinical practice and clinical trials. Stroke. 2011;42(2):427–32.
34. Patvardhan EA, Heffernan KS, Ruan JM, Soffler MI, Karas RH, Kuvin JT.
Assessment of vascular endothelial function with peripheral arterial
tonometry: information at your fingertips? Cardiol Rev. 2010;18(1):20–8.
35. Bloch KE, Schoch OD, Zhang JN, Russi EW. German version of the Epworth
Sleepiness Scale. Respiration. 1999;66(5):440–7.
36. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the
fatigue severity scale in a Swiss cohort. Sleep. 2008;31(11):1601–7.
37. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin
Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann
Intern Med. 1999;131(7):485–91.
38. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II.
San Antonio: Psychological Corporation; 1996.
39. R Core Team. R: a language and environment for statistical computing. Vienna:
R Foundation for Statistical Computing; 2019. https://www.R-projectorg/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Duss et al. Trials           (2021) 22:83 Page 11 of 11
